Impact of COVID-19 History on Hospital Stay Duration and Postoperative Complication Rates in Patients Undergoing VATS Lobectomy for Stage I and II Lung Cancer: A Retrospective Cohort Study

Öz

Objectives: This study investigates how a prior COVID-19 history influences hospital stay durations and postoperative complication rates among patients undergoing VATS lobectomy for stage I and II lung cancer between 2020 and 2024. Material and Method: A retrospective cohort study was conducted, including 145 patients who underwent VATS lobectomy at Şişli Etfal Hospital. Patients were divided into two groups: those with a history of COVID-19 (n=59) and those without (n=86). Data on demographics, clinical characteristics, hospital stay duration, and postoperative complications were collected and analyzed. Additionally, perioperative blood loss and the duration of chest tube placement were recorded for each patient. Patients who required more than 300 mL of drainage within the first 24 hours were carefully monitored, and further interventions were noted if necessary. Results: Additionally, the postoperative complication rate was higher in the COVID-19 group (36.5%) compared to the non-COVID-19 group (22.1%) (P < 0.05). Common complications included pneumonia, fever, and wound infection. Patients with a history of COVID-19 experienced a notably longer mean hospital stay (8.5 ± 3.7 days) compared to those without (5.2 ± 2.8 days).The perioperative blood loss was higher in patients with a history of COVID-19, with an average of 150 mL compared to 100 mL in the control group. Additionally, the chest tube duration was significantly prolonged in the COVID-19 group (6.2 ± 1.5 days) compared to the non-COVID-19 group (4.3 ± 1.2 days). Conclusion: These findings highlight the need for careful perioperative management and monitoring in this patient population. Patients with a prior history of COVID-19 undergoing VATS lobectomy exhibit prolonged hospital stays and increased postoperative complication rates.

Anahtar Kelimeler

• COVID-19
• VATS
• lung cancer

Kaynakça

1. 1. Ochani R, Asad A, Yasmin F, et al. COVID-19 pandemic: From origins to outcomes. A comprehensive review of viral pathogenesis, clinical manifestations, diagnostic evaluation, and management. Infez Med 2021;29(1):20-36.
2. 2. Habas K, Nganwuchu C, Shahzad F, et al. Resolution of coronavirus disease 2019 (COVID-19). Expert Rev Anti Infect Ther 2020;18(12):1201-1211. doi: 10.1080/14787210.2020.1797487. Epub 2020 Aug 4.
3. 3. Chan EG, Chan PG, Schuchert MJ. “Results of Surgical Treatment of Non-Small Cell Lung Cancer”. In: LoCicero J, Feins RH, Colson YL, Rocco G. Shields General Thoracıc Surgery. 8th Edition. Philadelphia: Lippincott Williams & Wilkins. 2019, pages 9321-9395.
4. 4. Shari B. Brosnahan, Annemijn H. Jonkman, Matthias C. Kugler, et al. COVID-19 and respiratory system disorders current knowledge, future clinical and translational research questions. Arterioscler Thromb Vasc Biol 2020;40:2586–2597. DOI: 10.1161/ATVBAHA.120.314515.
5. 5. Blanco JR, Cobos-Ceballos MJ, Navarro F, et al. Pulmonary long-term consequences of COVID-19 infections after hospital discharge. Clin Microbiol Infect 2021;27(6):892-896. doi: 10.1016/j.cmi.2021.02.019.
6. 6. Elrobaa IH, New KJ. COVID-19: Pulmonary and extra pulmonary manifestations. Front Public Health 2021;9:711616. doi: 10.3389/fpubh.2021.711616. eCollection 2021.
7. 7. Aziz MF, Schenning K, Koike S, et al. Perioperative mortality of the COVID-19 recovered patient compared to a matched control: A multicenter retrospective cohort study. Anesthesiology 2024; 140:195–206.
8. 8. Shao CC, McLeod MC, Thogaripally et al. Increased risk of postoperative mortality associated with prior COVID-19 infection. Am J Prev Med 2022;63(1S1):S75−S82.

9. 9. Cai Y, Hao Z, Gao Y, et al. Coronavirus Disease 2019 in the perioperative period of lung resection: A brief report from a single thoracic surgery department in Wuhan, people’s republic of China. Journal of Thoracic Oncology 2020;15(6):1065–72.
10. 10. Mo, X. Long-term lung function and related outcomes in COVID-19 survivors. American Journal of Respiratory and Critical Care Medicine 2020;(9):1372-1377.
11. 11. Del Rio C, Collins LF, Malani P. Long-term health consequences of COVID-19. JAMA 2020;324(17):1723-1724.
12. 12. Huang, C. Post-acute COVID-19 syndrome. Nature Medicine 2021;27(4):601-615.
13. 13. Carfì, A. Persistent symptoms in patients after acute COVID-19. JAMA 2020;324(6):603-605.
14. 14. Sato, R. Persistent inflammation and endothelial injury in COVID-19 survivors: A point of concern. Vascular Medicine 2021;26(3):309-312.
15. 15. Greenhalgh, T. Management of post-acute covid-19 in primary care. BMJ 2020;370:3026.
16. 16. Lee AYY, Connors JM. Anticoagulation in COVID-19: Dosing and outcomes. The Lancet Haematology 2021;8(6):e444-e445.